Skip to content
Menu

Blackstone Life Sciences To Provide Johnson & Johnson With $750M In R&D Funding To Support Phase 3 Clinical Development Of OLN324, An Investigational Therapy For Serious Retinal Vascular Diseases

Benzinga Newsdesk 1 hour ago

ContractsNews

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. ("Ollin").

The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.

Read at benzinga.com